retinai

Accelerate & Enhance Research with **RetinAI's Discovery® UNITY**

CHALLENGES

INCREASED TIME & RISK

Pharma pipelines from discovery to launch can take an average of **10-12 years**[1], at an average cost of **$2.6B**[2]. Significant **risk** is undertaken as only an average of 1 compound out of 10,000 is introduced to the market[3].

COMPETITION FOR PATIENT POPULATIONS

Therapies targeting similar pathways limit the market potential and the opportunity to personalize therapy with more well-defined assessment criteria.

SOLUTIONS

COLLABORATIVE RESEARCH

Enable **participative research** across the organization and with external experts using **secure, cloud-based access to data anytime and anywhere,** with insight from both certified and validated research modules for analysis.



HARMONIZE & AGGREGATE DATA FOR ANALYSIS AT SCALE

Leverage pharma's knowledge and past-trial experiences with capabilities to standardize data in a single ecosystem, and apply **AI analysis to extract insights about diseases, therapies and outcomes.**



ANALYZE PATIENT SUBGROUPS

Gain an in-depth understanding of patient's response to treatment by characterizing disease progression and outcomes. Divide population into sub-groups **to assess biomarker-based profiles and develop predictive analytics to save time and effort.**

[1]Deloitte. (2020). Intelligent Clinical Trials.
[2]Di Masi et al., (2016). Innovation in the pharmaceutical industry: New esteems of R&D costs. Journal of Health Economics, V. 47, pp. 20-30.
[3]The European Federation of Pharmaceutical Industries and Associations. (2022). Development of medicines.

retinai

RETINAI DISCOVERY® UNITY

RetinAI Discovery® UNITY is a powerful tool for pharma and research institutions to **accelerate and generate enhanced data insights at-scale across datasets and diseases.**

THE PLATFORM FEATURES

CLINICAL RESEARCH WORKFLOWS

Grading surveys and feedback collection for collaborative and independent data review, collecting additional data per image, visit or at patient level.

DISEASE FOCUS

AI models to support analysis in wet and dry AMD, Diabetic Retinopathy and Macular Edema, Retinal Vein Occlusion, Geographic Atrophy and Glaucoma.



MULTIMODAL DATA MANAGEMENT ANALYSIS

Multi-modal image and data management for OCT, FP, FAF and access to a library of certified and research use only AI modules for data understanding, analysis and patient progression prediction.

ENABLING THE RIGHT DECISION SOONER IN HEALTHCARE

FROM A STANDARD ANALYSIS WORKFLOW OF 6 MONTHS TO 6 WEEKS

Discovery has been used to aggregate clinical study data and RWE to analyze patient biomarkers and response to treatment at scale, accelerating customer's response to stakeholders and regulators.

ACCELERATED ANALYSIS WITH EXTENDED BIOMARKERS IN LARGE OCT STUDY

Expert-level analysis of AI biomarkers (fluid segmentation and quantification, segmentation) with a reduction in both time and cost associated with current research workflows for a study >15,000 OCTs.

To learn more about RetinAI and our tools, please visit www.retinai.com to schedule a demo.

DIS-UNI-2022-FLY-V2

RETINAI.COM | FREIBURGSTRASSE 3 – 3010 BERN, SWITZERLAND